Reshma Rangwala
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Endometrial and Cervical Cancer Treatments, Pancreatic and Hepatic Oncology Research, Ovarian cancer diagnosis and treatment
Most-Cited Works
- → Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer(2016)9,908 cited
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,153 cited
- → Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial(2017)525 cited
- → Combined MTOR and autophagy inhibition(2014)414 cited
- → Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study(2021)375 cited
- → Combined autophagy and proteasome inhibition(2014)372 cited
- → Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma(2014)358 cited
- → Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial(2017)346 cited
- → Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial(2017)235 cited
- → Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial(2019)221 cited